Basilea Pharmaceutica (VTX:BSLN) First Half 2023 Results

Key Financial Results

• Revenue: CHF84.9m (up 47% from 1H 2022).

• Net income: CHF31.8m (up from CHF12.2m loss in 1H 2022).

• Profit margin: 38% (up from net loss in 1H 2022). The move to profitability was primarily driven by higher revenue.

• EPS: CHF2.66 (up from CHF1.03 loss in 1H 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Basilea Pharmaceutica Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 31%. Earnings per share (EPS) also surpassed analyst estimates significantly.

Looking ahead, revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.

Performance of the market in Switzerland.

The company's shares are up 12% from a week ago.

Risk Analysis

You should learn about the 3 warning signs we've spotted with Basilea Pharmaceutica (including 2 which are significant).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.